UWCCC Developmental Therapeutics (DT) Program Summary Co-Leaders: Glenn Liu, Shigeki Miyamoto, and Jing Zhang PROJECT SUMMARY/ABSTRACT The mission of the UW Carbone Cancer Center (UWCCC) Developmental Therapeutics (DT) Program is to improve cancer patient outcomes by discovering new targets, developing therapeutic agents and biomarkers, and translating this research into early phase clinical trials. The DT Program provides the translational direction not only for DT members, but for other programs within the UWCCC (e.g. GEM, VR, TM). Clinical trial data and resources inform our understanding of response and resistance mechanisms and enable the identification of new therapeutic targets and treatment strategies to improve clinical outcomes. The DT Program has 59 core members, representing 18 departments and 5 different schools/colleges. Research impacts of DT members are evidenced by research awards totaling over $22.5M in annual direct cost of peer-reviewed and non-peer reviewed funding (including $3.45M NCI, $6.2M cancer-related other NIH agencies, $4.97M peer-reviewed non-NIH sources, $7.9M non-peer reviewed funding) and a significant number of publications (1228 publications, 18% of which result from intra-programmatic collaboration and 24% from inter-programmatic work). A key component of the new UWCCC Strategic Operating Plan is to further strengthen and develop Innovative Therapies and Cancer Biomarkers. Consistent with this strategic goal, the thematic aims of the DT Program are to: 1) discover new molecular targets for cancer therapy; 2) develop new agents and biomarkers; and 3) translate new therapies and biomarkers into clinical trials. To achieve this goal, it is critical to have a very strong program that discovers, develops, and translates novel interventions and biomarkers. To this end, members of the DT Program come from basic science, applied science, and clinical departments. This program has expertise ranging from basic discovery (molecular pathways and targets), to development (drugs/assays/biomarkers), to early clinical translation application (Phase 1 clinical trials). Translational and clinical research DT program members apply intra- and inter-programmatic research discoveries in clinical trials, performing the majority of first-in-human or early phase clinical trials, while individual disease-specific research teams (Disease Oriented Teams) focus primarily on phase 2 and 3 studies. DT members lead or participate in all clinical research groups facilitating both translational and reverse-translational opportunities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014520-45
Application #
9706771
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-04-01
Budget End
2020-03-31
Support Year
45
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Pleiman, Jennifer K; Irving, Amy A; Wang, Zhishi et al. (2018) The conserved protective cyclic AMP-phosphodiesterase function PDE4B is expressed in the adenoma and adjacent normal colonic epithelium of mammals and silenced in colorectal cancer. PLoS Genet 14:e1007611
Kletzien, Heidi; Macdonald, Cameron L; Orne, Jason et al. (2018) Comparison Between Patient-Perceived Voice Changes and Quantitative Voice Measures in the First Postoperative Year After Thyroidectomy: A Secondary Analysis of a Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg 144:995-1003
Kang, Lei; Jiang, Dawei; Ehlerding, Emily B et al. (2018) Noninvasive Trafficking of Brentuximab Vedotin and PET Imaging of CD30 in Lung Cancer Murine Models. Mol Pharm 15:1627-1634
Bulu, Hakan; Sippo, Dorothy A; Lee, Janie M et al. (2018) Proposing New RadLex Terms by Analyzing Free-Text Mammography Reports. J Digit Imaging 31:596-603
Jewett, Patricia I; Gangnon, Ronald E; Elkin, Elena et al. (2018) Geographic access to mammography facilities and frequency of mammography screening. Ann Epidemiol 28:65-71.e2
Albertini, Mark R (2018) The age of enlightenment in melanoma immunotherapy. J Immunother Cancer 6:80
Shull, James D; Dennison, Kirsten L; Chack, Aaron C et al. (2018) Rat models of 17?-estradiol-induced mammary cancer reveal novel insights into breast cancer etiology and prevention. Physiol Genomics 50:215-234
Kang, Lei; Jiang, Dawei; England, Christopher G et al. (2018) ImmunoPET imaging of CD38 in murine lymphoma models using 89Zr-labeled daratumumab. Eur J Nucl Med Mol Imaging 45:1372-1381
Melgar-Asensio, Ignacio; Kandela, Irawati; Aird, Fraser et al. (2018) Extended Intravitreal Rabbit Eye Residence of Nanoparticles Conjugated With Cationic Arginine Peptides for Intraocular Drug Delivery: In Vivo Imaging. Invest Ophthalmol Vis Sci 59:4071-4081
Jang, Samuel; Rosenberg, Stephen A; Hullet, Craig et al. (2018) Value of Elective Radiation Oncology Rotations: How Many Is Too Many? Int J Radiat Oncol Biol Phys 100:558-559

Showing the most recent 10 out of 1528 publications